OBIO Key Statistics, Chart & Performance
The current stock price of OBIO is 3.93 USD. In the past month the price decreased by -6.65%. In the past year, price decreased by -25%.
OBIO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to OBIO. When comparing the yearly performance of all stocks, OBIO is a bad performer in the overall market: 80.39% of all stocks are doing better.
OBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OBIO. The financial health of OBIO is average, but there are quite some concerns on its profitability.
OBIO Financial Highlights
Over the last trailing twelve months OBIO reported a non-GAAP Earnings per Share(EPS) of -1.81. The EPS decreased by -12.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.66% | ||
| ROE | -171.7% | ||
| Debt/Equity | 0.32 |
OBIO Forecast & Estimates
14 analysts have analysed OBIO and the average price target is 13.99 USD. This implies a price increase of 255.94% is expected in the next year compared to the current price of 3.93.
For the next year, analysts expect an EPS growth of -7.43% and a revenue growth 6.59% for OBIO
OBIO Ownership
About OBIO
Company Profile
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania and currently employs 70 full-time employees. The company went IPO on 2020-08-04. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The firm develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
Company Info
ORCHESTRA BIOMED HOLDINGS IN
150 Union Square Drive
New Hope PENNSYLVANIA US
Employees: 70
Phone: 16463439298
ORCHESTRA BIOMED HOLDINGS IN / OBIO FAQ
Can you describe the business of ORCHESTRA BIOMED HOLDINGS IN?
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania and currently employs 70 full-time employees. The company went IPO on 2020-08-04. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The firm develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
Can you provide the latest stock price for ORCHESTRA BIOMED HOLDINGS IN?
The current stock price of OBIO is 3.93 USD. The price decreased by -5.53% in the last trading session.
What is the dividend status of ORCHESTRA BIOMED HOLDINGS IN?
OBIO does not pay a dividend.
How is the ChartMill rating for ORCHESTRA BIOMED HOLDINGS IN?
OBIO has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is ORCHESTRA BIOMED HOLDINGS IN (OBIO) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on OBIO.
What is the market capitalization of OBIO stock?
ORCHESTRA BIOMED HOLDINGS IN (OBIO) has a market capitalization of 221.89M USD. This makes OBIO a Micro Cap stock.